PRA Health Sciences (NASDAQ:PRAH) Buy Rating Reaffirmed Today By Robert W. Baird; The PT is Set to $91.0

January 13, 2018 - By Marguerite Chambers

 PRA Health Sciences (NASDAQ:PRAH) Buy Rating Reaffirmed Today By Robert W. Baird; The PT is Set to $91.0

PRA Health Sciences (NASDAQ:PRAH) Rating Reaffirmed

The company has just set a price target of $91.0 on PRA Health Sciences (NASDAQ:PRAH) shares. This is 1.04 % from the last stock price. In a note revealed to clients and investors on 26 October, Robert W. Baird reaffirmed their Buy rating on shares of PRAH.

PRA Health Sciences, Inc. (NASDAQ:PRAH) Ratings Coverage

Among 15 analysts covering PRA Health Sciences (NASDAQ:PRAH), 11 have Buy rating, 0 Sell and 4 Hold. Therefore 73% are positive. PRA Health Sciences has $102 highest and $43 lowest target. $89.42’s average target is -0.71% below currents $90.06 stock price. PRA Health Sciences had 35 analyst reports since July 22, 2015 according to SRatingsIntel. Jefferies maintained PRA Health Sciences, Inc. (NASDAQ:PRAH) on Thursday, June 1 with “Buy” rating. The firm has “Buy” rating given on Monday, March 28 by SunTrust. Citigroup upgraded the shares of PRAH in report on Wednesday, May 4 to “Buy” rating. Robert W. Baird maintained it with “Buy” rating and $88.0 target in Monday, October 9 report. Credit Suisse initiated it with “Neutral” rating and $43 target in Tuesday, June 21 report. The stock of PRA Health Sciences, Inc. (NASDAQ:PRAH) earned “Neutral” rating by SunTrust on Thursday, November 19. The company was maintained on Thursday, October 26 by Credit Suisse. The stock of PRA Health Sciences, Inc. (NASDAQ:PRAH) has “Buy” rating given on Thursday, December 14 by MUFG Securities Americas Inc. On Monday, October 16 the stock rating was maintained by KeyBanc Capital Markets with “Buy”. The stock of PRA Health Sciences, Inc. (NASDAQ:PRAH) has “Neutral” rating given on Thursday, November 19 by Suntrust Robinson.

The stock decreased 1.40% or $1.28 during the last trading session, reaching $90.06. About 353,127 shares traded. PRA Health Sciences, Inc. (NASDAQ:PRAH) has risen 52.22% since January 13, 2017 and is uptrending. It has outperformed by 35.52% the S&P500.

Analysts await PRA Health Sciences, Inc. (NASDAQ:PRAH) to report earnings on February, 28. They expect $1.00 earnings per share, up 47.06 % or $0.32 from last year’s $0.68 per share. PRAH’s profit will be $63.37M for 22.52 P/E if the $1.00 EPS becomes a reality. After $0.82 actual earnings per share reported by PRA Health Sciences, Inc. for the previous quarter, Wall Street now forecasts 21.95 % EPS growth.

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company has market cap of $5.71 billion. The firm offers integrated services, such as data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It has a 50.23 P/E ratio. It also provides product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

More news for PRA Health Sciences, Inc. (NASDAQ:PRAH) were recently published by: Prnewswire.com, which released: “Free Research Reports on These Healthcare Stocks — Tivity Health, PRA Health …” on December 27, 2017. Nasdaq.com‘s article titled: “PRA Health (PRAH) Hits 52-Week High on Multiple Positives” and published on December 26, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.